For drugs prone to degradation in the harsh gastrointestinal environment, the dry powder form can be formulated into capsules or tablets. Once ingested, they rapidly form liposomes that protect the payload and enhance absorption across the intestinal mucosa, addressing critical issues of low oral bioavailability.
Proliposome based Targeted Drug Delivery Solution
In the pursuit of groundbreaking therapies, the journey from a promising molecule to a viable treatment often stalls at the single, formidable obstacle of formulation stability. Protecting fragile nucleic acids and guiding therapeutics to their precise site of action are challenges that conventional liquid liposomes often fail to consistently meet during long-term storage. Our Proliposomes-based Delivery Systems Solution helps you accelerate drug discovery and enhance therapeutic efficacy through advanced stabilization and customizable drug loading techniques, transforming the delivery phase into a reliable asset for your project.
Click Here to View more about our Services
Introduction of Proliposomes
Proliposomes (PLs) are defined as dry, free-flowing granular powders composed of phospholipid precursors and therapeutic agents that, upon simple addition of an aqueous medium (hydration), rapidly form a standard liposomal suspension. This innovative pre-liposomal technology was developed primarily to circumvent the inherent poor physical and chemical stability of ready-to-use liposomal dispersions, which can degrade or aggregate during storage.
Structure and Function
The core structure of a proliposome involves phospholipids (often combined with stabilizers like cholesterol) adsorbed onto an inert, porous, water-soluble carrier material, such as maltodextrin or sorbitol. The drug is incorporated either within the lipid matrix or encapsulated alongside it. The key function of this configuration is stabilization. By converting the liquid liposome into a solid, anhydrous form, the system effectively arrests the degradation pathways, such as hydrolysis and oxidation, that occur in aqueous media. This results in a product that is easy to handle, transport, and store for extended periods. When the formulation is rehydrated, the adsorbed phospholipids spontaneously self-assemble into bilayer vesicles, forming a homogeneous liposomal suspension ready for administration.
Scientific literature confirms the substantial benefits of proliposomes in drug delivery. Research indicates that the transformation from a dry powder to active liposomes is rapid and results in vesicles with comparable or superior encapsulation efficiency and size distribution uniformity compared to conventional methods. The stability achieved allows for wider applicability, particularly for compounds requiring ambient storage or delivery via non-traditional routes. The use of proliposomes is a recognized strategy to enhance the bioavailability of hydrophobic drugs and protect sensitive molecules, thereby increasing the reliability and consistency of pharmaceutical products.
Applications of Proliposomes in Drug Development
The inherent stability and ease of reconstitution make proliposomes a highly attractive platform for various advanced therapeutic applications. Their dry state offers distinct advantages in specific administration contexts:
Oral Drug Delivery
Pulmonary and Nasal Delivery
Proliposomes are perfectly suited for dry powder inhaler (DPI) or nasal spray applications. The micronized powder can be directly administered to the lungs or nasal passages, where the natural moisture reconstitutes them into lung-lining fluid-compatible liposomes. This allows for localized treatment or systemic delivery with high efficiency and minimized first-pass metabolism.
Transdermal Systems
When incorporated into gels or patches, proliposomes can improve the skin permeability of therapeutic agents. The liposomal structure formed upon contact with the skin's moisture promotes efficient partitioning and deep penetration of the drug across the epidermal barrier.
Vaccine and Gene Therapy
The system provides a stable, temperature-independent format for lipid-based delivery of nucleic acids (mRNA, siRNA) and antigens. This addresses the cold-chain logistics challenge, making advanced therapies accessible in diverse settings.
Practical Research and Experimental Case Studies
Antiviral Delivery to Poultry (Ivermectin)
Researchers developed and optimized Ivermectin (IVM)-loaded proliposomes (PLs) using a full factorial design against the Infectious Bronchitis Virus (IBV) in embryonated chicken eggs. The optimized PLs showed high entrapment efficiency (up to 96.1%) and reduced toxicity compared to pure IVM. The PL-treated group exhibited a significantly lower mortality rate and further reduction in IBV copies via qRT-PCR, demonstrating that PLs are a potentially effective anti-viral delivery system for use in poultry.2,4
Enhancing Oral Bioavailability (Dehydrosilymarin)
This study prepared dehydrosilymarin-loaded proliposomes (PLs) using a film dispersion-freeze drying method to improve the drug's oral absorption, which is hindered by poor solubility. In in vivo studies using rats, the PL formulation significantly enhanced the oral bioavailability of dehydrosilymarin compared to the free drug. The results indicated that using PLs could overcome the solubility issues and provide a feasible solution for improving the oral delivery efficiency of similar hydrophobic compounds.3,4
What We Can Offer
Creative Biolabs offers a fully customized, integrated suite of services for the design, synthesis, and characterization of cutting-edge Proliposomes-based Delivery Systems. We collaborate with you at every stage, from lipid selection to final product optimization.
Custom Proliposome Formulation Development
Tailored design of the lipid mixture (phospholipids, cholesterol, stabilizing agents) and carrier material for optimal drug loading and liposome characteristics upon hydration.
High-Efficiency Drug Loading
Expertise in incorporating diverse payloads, including small-molecule drugs, peptides, proteins, and nucleic acids, into the proliposome matrix using techniques like vacuum-drying, spray-drying, or fluid-bed granulation.
Targeted Proliposome Precursor Engineering
Development of proliposome formulations that, upon reconstitution, display targeting ligands (peptides, antibodies, aptamers) on the resulting liposome surface for site-specific delivery.
Advanced Characterization and Quality Control
Comprehensive analysis of the dry powder (flowability, residual moisture) and the reconstituted liposomes (size distribution, zeta potential, encapsulation efficiency, drug release kinetics).
Stability and Shelf-Life Testing
Rigorous accelerated and long-term stability studies performed on the dry proliposome formulation to meet regulatory requirements and guarantee product longevity.
FAQs
What are the main limitations of conventional lipid-based vesicles, and how does this dry-powder approach resolve them?
The primary limitation of traditional aqueous lipid vesicles is their long-term instability. Over time in a liquid medium, the lipids can undergo hydrolysis, oxidation, or fusion, leading to drug leakage and particle aggregation. The dry-powder precursor approach resolves this by completely removing the aqueous phase, which is necessary for these degradation mechanisms, thereby locking the components in a highly stable solid state that can last for years at ambient temperature.
Can these delivery systems accommodate both water-soluble and oil-soluble therapeutic compounds?
Yes, this system is versatile. The final liposome structure, once formed, consists of a lipid bilayer surrounding an aqueous core. Water-soluble compounds are typically entrapped within the aqueous core, while oil-soluble (hydrophobic) compounds integrate directly into the lipid bilayer structure itself. The precursor formulation process is optimized to ensure efficient placement and high-yield encapsulation for both types of molecules.
Does the hydration process compromise the structural integrity or homogeneity of the resulting vesicles?
When formulated correctly, the spontaneous self-assembly of lipids upon hydration is highly controlled and rapid. High-quality precursor formulations yield liposomes that are structurally intact and maintain a tight, uniform size distribution comparable to, or sometimes better than, vesicles prepared directly in liquid phase. Thorough quality control checks, including dynamic light scattering (DLS), are critical to confirm the uniformity of the resulting suspension.
How does the size and uniformity of the reconstituted vesicles impact therapeutic efficacy?
Vesicle size and uniformity are crucial factors. Smaller, uniform vesicles typically exhibit superior circulation times and better penetration into target tissues. Furthermore, size control is essential for sterile filtration and regulatory approval. Our system is designed to provide excellent control over these parameters, often resulting in small (<200 nm), monodisperse liposomes optimal for systemic or localized delivery.
For pulmonary or nasal administration, are there specific concerns regarding the carrier material used in the dry-powder formulation?
For pulmonary and nasal routes, the carrier material must be biocompatible, safe for inhalation/mucosal contact, and rapidly soluble in the physiological fluids of the administration site. Common carriers like saccharides (e.g., lactose, mannitol) are chosen specifically for their excellent safety profiles, ability to enhance powder flowability, and quick dissolution, leaving behind only the active, reconstituted liposomes at the target site.
Creative Biolabs' Proliposomes-based Delivery Systems Solution offers a robust, stability-focused alternative to conventional drug carriers, ensuring your therapeutic agents maintain their integrity and efficacy from bench to bedside. Our end-to-end services encompass tailored formulation, advanced quality control, and scalable manufacturing design, positioning your project for accelerated success.
Reference
- Alyami, Mohammad H et al. "Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model." Pharmaceutics vol. 17,2 165. 25 Jan. 2025, https://doi.org/10.3390/pharmaceutics17020165.
- Chu, Chang et al. "Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo." Acta pharmacologica Sinica vol. 32,7 (2011): 973-80, https://doi.org/10.1038/aps.2011.25.
- Distributed under Open Access license CC BY 4.0, without modification.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
